



Full paper/Mémoire

## Unexpected reaction of melatonin derivatives with performic acid

Zuzanna Mołęda<sup>a</sup>, Anna Zawadzka<sup>a</sup>, Małgorzata Żytek<sup>a</sup>, Daria Madej<sup>a</sup>, Franciszek Pluciński<sup>b</sup>, Jan K. Maurin<sup>b,c</sup>, Zbigniew Czarnocki<sup>a,\*</sup><sup>a</sup> Faculty of Chemistry, University of Warsaw, Pasteura 1, 02-093 Warszawa, Poland<sup>b</sup> National Medicines Institute, Chelmska 30/34, 00-725 Warszawa, Poland<sup>c</sup> National Centre for Nuclear Research, Sołtana 7, 05-400 Otwock-Świerk, Poland

## ARTICLE INFO

## Article history:

Received 11 January 2013

Accepted after revision 18 March 2013

Available online 24 April 2013

## Keywords:

Cyclization

Indoles

Oxygenations

Rearrangement

Ring closure

## ABSTRACT

A series of carbamate melatonin derivatives was treated with performic acid, providing tricyclic products with a 3-hydroxytetrahydropyrrolo[2,3-*b*]indole skeleton. An unusual migration of carbamate groups was observed in some cases, and the reaction appeared to be strongly dependent on the type of substituent in the phenyl ring of the phenylcarbamate group. Theoretical calculations suggest that the reaction is kinetically controlled.

© 2013 Académie des sciences. Published by Elsevier Masson SAS. All rights reserved.

## R É S U M É

Une série de dérivées de la mélatonine carbamate a été traitée avec de l'acide performique, fournissant des produits tricycliques avec un squelette 3-hydroxytétrahydropyrrolo [2,3-*b*] indole. Une migration inhabituelle des groupes carbamate a été observée dans certains cas, et la réaction a semblé être fortement dépendante du type de substituant sur le noyau phényle du groupe phénylcarbamate.

© 2013 Académie des sciences. Publié par Elsevier Masson SAS. Tous droits réservés.

## 1. Introduction

3a-Hydroxytetrahydropyrrolo[2,3-*b*]indole is the structural motif characteristic of many compounds of high biological importance, such as notoamide D – obtained from a culture of marine-derived fungus *Aspergillus* sp. and which demonstrated noticeable cytotoxicity on HeLa and L-1210 tumor cells [1] –, gypsetin – derived from dermatophyte *Nannizzia gypsea* and which confirmed acyl-CoA acyltransferase inhibitory activity [2] – or himastatin – a new anti-tumor antibiotic from *Streptomyces hygroscopicus* [3]. Among the several possible methods for the synthesis of this system [4], oxidative



cyclization of indole derivatives seems to be the simplest one [5]. An example of such reaction is the oxidation of melatonin **1** with singlet oxygen, in the presence of photosensitizers, such as Bengal rose at –78 °C, to produce cyclic 3-hydroxymelatonin **2** [6] (Scheme 1).

We have recently demonstrated that compounds possessing a carbamate substituent at position 5 of the 3a-hydroxytetrahydropyrrolo[2,3-*b*]indole skeleton exhibit a high inhibitory activity against human cholinesterases [7]. This type of compounds represents an interesting synthetic target, poorly explored so far.

It was reported that the oxidation of carbamate melatonin derivatives with singlet oxygen results in the cyclization to 3a-hydroxytetrahydropyrrolo[2,3-*b*]indole system [7]. Unfortunately, this method turns out to be time-consuming and merely effective due to a low degree of conversion.

\* Corresponding author.

E-mail address: czarnoz@chem.uw.edu.pl (Z. Czarnocki).

Scheme 1. Oxidation of melatonin **1** with singlet oxygen.Scheme 2. Oxidation of 3-[2-(acetylamino)ethyl]-1H-indol-5-yl carbamates **3**, **5** and **7** with performic acid.

## 2. Results and discussion


We have, therefore, investigated a series of reactions of melatonin **1** and its derivatives with different oxidative reagents, in order to find an easy and more efficient method for the synthesis of the desirable tricyclic system. Unfortunately, we found that the oxidation with  $\text{H}_2\text{O}_2$ ,  $\text{NaOCl}$ ,  $\text{MnO}_2$ ,  $\text{SeO}_2$ ,  $\text{CrO}_3$ , Oxone<sup>®</sup>, or Sharpless epoxidating reagent was, depending on the conditions used, either completely ineffective, or resulted in the decomposition of the substrate to unidentifiable products. Attempts to oxidize melatonin **1** with peracids seemed to be the most promising.


In order to obtain the 3a-hydroxytetrahydropyrrolo-[2,3-*b*]indole skeleton substituted at position 5 with a carbamate group, we subjected 3-[2-(acetylamino)ethyl]-1H-indol-5-yl carbamates to a reaction with performic acid, freshly prepared by adding  $\text{H}_2\text{O}_2$  to concentrated formic acid according to the known procedure [8] (Scheme 2).

We were pleased to observe the fast consumption of the substrate as well as the formation of a single product, easy to isolate. The oxidation of 3-[2-(acetylamino)ethyl]-1H-indol-5-yl phenylcarbamate **3** resulted in the desired tricyclic product **4**, with undisturbed carbamate moiety. An additional formulation of the N8 atom occurred, which

can be explained by the already documented formulating ability of performic acid [9]. Postulated structure of the product was confirmed by X-ray analysis (Fig. 1).

In the case of carbamates **5** and **7**, we obtained similar results. The reaction yields were not high but still satisfying in comparison with the methods used so far. This disadvantage was in addition compensated by the

Fig. 1. ORTEP diagram from X-ray analysis of compound **4**<sup>1</sup>.



**Scheme 3.** Oxidation of 3-[2-(acetylmino)ethyl]-1H-indol-5-yl carbamates **9**, **11** and **13** with performic acid.

simplicity of the reaction and purification procedure and the low cost of the reagents used. The substrates may be easily recovered and recycled. The yields calculated on a basis of the consumed substrates were almost quantitative.

Hoping to have in hand a general method for the synthesis of tricyclic carbamates, we decided to broaden the spectrum of the investigated substituents at the aromatic ring of the phenylcarbamate moiety. Therefore, we used the previously optimized methodology to oxidize *o*-isopropylphenyl-, *p*-isopropylphenyl- and *o*-methoxyphenyl-carbamates (Scheme 3).

Similarly to our previous results, we observed the formation of a single product with the yield of around 30%. In the NMR spectra, we identified signals characteristic of the tricyclic system but, surprisingly, no signal from the expected formyl group was present. The mass spectrometry analysis confirmed the absence of the formyl substituent in all the three cases mentioned. For the products possessing *p*-isopropyl substituents, we

succeeded to obtain a monocrystal suitable for X-ray analysis and we were surprised to find out that the carbamate bond hydrolyzed and the released group formed a urea bond with the N8 atom of the tricyclic system (Figs. 2 and 3). Detailed spectral analysis further confirmed the proposed structure of the products **10**, **12** and **14**.

Surprised by the difference in the results obtained for carbamates **3**, **5**, **7** and **9**, **11**, **13**, we repeated all the reactions several times, changing the concentration of the oxidizing agent and we gained a conviction that it does not affect the type of product. We can then assume that the structure of the product depends only on the substrate used. Unexpected influence of the substituent at the phenyl ring on the reaction course can be attributed to the presence of a conjugated bonds system, which covers a considerable part of the molecule of the substrate and can generate unexpectedly strong long-distance electronic effects. In order to rationalize the differences in the reactivity of various carbamates with performic acid, we



Fig. 2. ORTEP diagram from X-ray analysis of compound **10**<sup>2</sup>. For interpretation of colors, see the web version of this article.




Fig. 3. ORTEP diagram from X-ray analysis of compound **12**<sup>3</sup>. For interpretation of colors, see the web version of this article.

initially concentrated on the thermodynamic aspects of this reaction. The complete set of free enthalpy ( $\Delta G^0$ ) values for all the reactions leading to the products, both observed and hypothetical (Fig. 4) were calculated using the Spartan 08 software [10]. Ab initio calculations using density functional method at B3LYP level with 6–31 + G\*

Table 1

Comparison of free energy values for reactions leading to formed and hypothetical products.

Entry	Substituent	Reaction	$\Delta G^0$ [kJ/mol]
1	<i>p</i> -Cl	$G^0(\mathbf{6})-G^0(\mathbf{5})$	-66.8
2	<i>p</i> -Cl	$G^0(\mathbf{15})-G^0(\mathbf{5})$	-76.0
3	<i>o</i> -NO <sub>2</sub>	$G^0(\mathbf{8})-G^0(\mathbf{7})$	-75.3
4	<i>o</i> -NO <sub>2</sub>	$G^0(\mathbf{16})-G^0(\mathbf{7})$	-57.0
5	<i>o</i> -OCH <sub>3</sub>	$G^0(\mathbf{14})-G^0(\mathbf{13})$	-67.1
6	<i>o</i> -OCH <sub>3</sub>	$G^0(\mathbf{17})-G^0(\mathbf{13})$	-75.2





Fig. 4. The structures of the alternative products **15**, **16**, **17** used for calculations.

function basis were performed. The structure of the molecules of the products and substrates were optimized and their free enthalpies were calculated. The results are summarized in Table 1.

These results of calculations indicate that due to rather minute differences in  $\Delta G^0$  values, the thermodynamic influence is not significant and apparently the reaction is governed by kinetic factors.

The course of the reaction, leading to unexpected products listed in Scheme 3, might be explained by a process starting with the protonation of the carbamate oxygen atom followed by the formation of the reaction intermediate whose sandwich-like dimeric structure allows the simultaneous transfer of both carbamate units between the molecules and the subsequent formation of the observed product. The example of such reaction sequence for compound **13** is shown in Scheme 4. We are aware that such a process might be highly unfavourable, leading to a dimeric structure of an extremely high energy and the real reaction course is probably a multi-step process but we hoped that our model would at least illustrate the tendency to the appropriate bonds forming/breaking sequence.

We, therefore, compared two alternative processes of the dissociation of the hypothetical dimeric structures: the



Scheme 4. The postulated mechanism for the formation of product **14**.




Fig. 5. The optimized structure of postulated intermediate **13a**. For interpretation of colors, see the web version of this article.

Table 2

The comparison of energies (in kJ/mol) of alternative dissociation processes.

Intermediate	$\Delta E$		$\Delta\Delta E$
	C–N dissociation	C–O dissociation	
<b>5a</b>	–6199.0	–6252.4	53.4
<b>7a</b>	–6202.2	–6223.2	21.0
<b>13a</b>	–6358.6	–6041.8	–316.8

first one consisting in the dissociation of the C–N bonds (shown in red in Scheme 4) leading to a “normal” product without rearrangement, and the second one consisting in the dissociation of the phenolic C–O bond (marked in blue in Scheme 4) leading to “rearranged” products.

To establish the energy of each process, we performed an ab initio optimization of the structures of the respective dimers (Fig. 5) and the corresponding monomers and then, we compared the energy differences:

$$\Delta E_{\text{process}} = 2E_{\text{monomer}} - E_{\text{dimer}}$$

Indeed, very high  $\Delta E$  values of the processes encompass not only bond energies but also repulsion and deformation energies. The last column in Table 2 denoted as  $\Delta\Delta E$  contains the differences between dissociation energies listed in columns 2 and 3. These values show a possible gain in energy when a new C–N bond is formed in a product with a simultaneous dissociation of the existing C–O bond. In all instances where such value is positive, the process is unfavourable whereas negative value corresponds to a net energy gain. The comparison of the energies listed in Table 2 leads to the conclusion that the rearrangement process, i.e. the breaking the C–O bond, is preferred for intermediate **13a**, whereas for the two others (**5a** and **7a**), the preferred one is the dissociation or more exactly the non-formation of C–N bonds. These results are in agreement with the experimental observations and seem to confirm a plausible mechanism for the observed rearrangement.

### 3. Conclusion

In summary, we found that certain melatonin derivatives possessing a carbamate moiety, when treated with

performic acid form the corresponding 3-hydroxytetrahydro-pyrrolo[2,3-*b*]indoles. An unusual migration of carbamate groups was observed in some cases, and the reaction appeared to be strongly dependent on the type of substituent in the phenyl ring of the phenylcarbamate group. Theoretical calculations suggest that the reaction is kinetically controlled.

### 4. Experimental

Anhydrous solvents were used for all the reactions. TLC analyses were performed on silica gel plates (Merck Silica Gel 60 F254) and made visual using a UV lamp and  $I_2$  vapor. The melting points were determined on a Boetius hot-plate microscope and are uncorrected. Column chromatography was carried out at atmospheric pressure using Merck Silica Gel 60 (100–200 mesh) or  $Al_2O_3$  using mixtures of cyclohexane–ethyl acetate or diethyl ether–methanol as eluents. The NMR spectra were recorded on a Varian Unity Plus spectrometer operating at 200 MHz or 500 MHz for  $^1H$  NMR and at 50 MHz or 125 MHz for  $^{13}C$  NMR. The spectra were measured in  $CDCl_3$ ,  $CD_3OD$  and  $DMSO-d_6$  and chemical shifts ( $\delta$ ) are reported in ppm relative to TMS. Mass spectra were obtained using Quattro LC Micromass and LCT Micromass TOF HiRes apparatus. 3-[2-(acetylamino)ethyl]-1*H*-indol-5-yl carbamates **3**, **5**, **7**, **9**, **11** and **13** were prepared according to the known procedure [7]. The X-ray data were collected using Oxford Diffraction Xcalibur R single crystal diffractometer. Data were collected at room temperature by the application of Cu  $K\alpha$  monochromatic radiation. The structures were solved using SHELXS-93 program [10] and then refined by the application of SHELXL-93 software [10]. Full structural data have been deposited with the Cambridge Crystallographic Data Centre under respective numbers CCDC 910337<sup>1</sup>, CCDC 910338<sup>2</sup>, and CCDC 910339<sup>3</sup>.

#### 4.1. Oxidation of *N*-acetylserotonin carbamates with performic acid. General procedure

Performic acid was freshly prepared by adding 30%  $H_2O_2$  (0.5 mL) to 98% formic acid (9.5 mL) and stirring at room temperature for 2 h.

3-[2-(acetylamino)ethyl]-1*H*-indol-5-yl carbamate was dissolved in 98% formic acid (2 mL). The mixture was cooled to 0 °C and performic acid (1.1 equiv) was added. The mixture was stirred at 0 °C for 2 h and washed with 10% aqueous  $Na_2SO_3$  solution (10 mL).  $Na_2CO_3$  (2 g) was added successively. The mixture was extracted with  $CHCl_3$  (2 × 15 mL). The organic layer was dried over anhydrous  $MgSO_4$  and concentrated.

<sup>1</sup> The detailed structural parameters have been deposited with the Cambridge Crystallographic Data Centre under the number CCDC 910337.

<sup>2</sup> The detailed structural parameters have been deposited with the Cambridge Crystallographic Data Centre under the number CCDC 910338.

<sup>3</sup> The detailed structural parameters have been deposited with the Cambridge Crystallographic Data Centre under the number CCDC 910339.

#### 4.1.1. 1-Acetyl-8-formyl-3a-hydroxy-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate 4

The residue was purified by column chromatography (silica gel, 0–5% MeOH–Et<sub>2</sub>O) to give a white solid; yield: 168 mg (30%); mp 154–157 °C. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ = 2.09 (s, 3 H, COCH<sub>3</sub>), 2.46–2.57 (m, 2 H, CH<sub>2</sub>), 3.18 (m, 1 H, CHH), 3.87 (t, 1 H, *J* = 9.0 Hz, CHH), 5.87 (s, 1 H, *H*-8a), 7.07 (t, 1 H, *J* = 7.0 Hz), 7.23 (dd, 1 H, *J*<sub>1</sub> = 2.0 Hz, *J*<sub>2</sub> = 9.0 Hz), 7.32 (t, 2 H, *J* = 8.0 Hz), 7.38 (d, 1 H, *J* = 2.0 Hz), 7.51 (d, 2 H, *J* = 7.5 Hz), 8.02 (d, 1 H, *J* = 8.5 Hz), 8.96 (s, 1 H, CHO). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): δ = 21.01, 36.41, 46.84, 80.65, 85.18, 117.44, 117.98, 118.70, 123.37, 123.70, 128.81, 134.84, 138.57, 138.63, 148.48, 152.94, 163.31, 172.27. HRMS (ESI): *m/z* [M+Na]<sup>+</sup> calcd for C<sub>20</sub>H<sub>19</sub>N<sub>3</sub>O<sub>5</sub>Na: 404.1223, found: 404.1226. X-ray analysis<sup>1</sup>.

#### 4.1.2. 1-Acetyl-8-formyl-3a-hydroxy-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl (4-chlorophenyl)carbamate 6

The residue was purified by column chromatography (silica gel, 50–100% AcOEt–cC<sub>6</sub>H<sub>12</sub>) to give a white solid; yield: 53 mg (39%); mp 177–180 °C. <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>): δ = 2.01 (s, 3H, COCH<sub>3</sub>), 2.39–2.50 (m, 2 H, CH<sub>2</sub>), 3.04 (m, 1 H, CHH), 3.82 (t, 1 H, *J* = 9.6 Hz, CHH), 5.76 (s, 1 H, *H*-8a), 6.36 (s, 1 H), 7.22 (dd, 1 H, *J*<sub>1</sub> = 2.4 Hz, *J*<sub>2</sub> = 8.7 Hz), 7.39 (d, 2 H, *J* = 9.0 Hz), 7.40 (s, 1 H), 7.54 (d, 2 H, *J* = 9.0 Hz), 7.89 (d, 1 H, *J* = 9.0 Hz), 8.87 (s, 1 H, CHO). <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>): δ = 22.11, 36.60, 46.42, 79.95, 84.72, 116.44, 118.08, 119.97, 123.22, 126.68, 128.78, 135.21, 137.60, 138.29, 147.17, 151.76, 162.25, 170.19. HRMS (ESI): *m/z* [M+Na]<sup>+</sup> calcd for C<sub>20</sub>H<sub>18</sub>N<sub>3</sub>O<sub>5</sub>ClNa: 438.0833, found: 438.0835.

#### 4.1.3. 1-Acetyl-8-formyl-3a-hydroxy-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl (2-nitrophenyl)carbamate 8

The residue was purified by column chromatography (silica gel, AcOEt) to give a yellow oil; yield: 13 mg (12%). <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>): δ = 2.05 (s, 3 H, COCH<sub>3</sub>), 2.52 (m, 2 H, CH<sub>2</sub>), 3.14–3.28 (m, 1 H, CHH), 3.70–3.79 (m, 1 H, CHH), 3.95 (br.s, 1 H, OH), 5.88 (s, 1 H, *H*-8a), 7.18–7.32 (m, 3 H), 7.68 (t, 1 H, *J* = 7.8 Hz), 8.04 (d, 1 H, *J* = 8.4 Hz), 8.27 (dd, 1 H, *J*<sub>1</sub> = 1.6 Hz, *J*<sub>2</sub> = 8.7 Hz), 8.51 (d, 1 H, *J* = 7.6 Hz), 8.87 (s, 1 H, CHO). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>): δ = 22.15, 37.12, 46.68, 80.20, 85.51, 117.30, 117.94, 120.80, 123.15, 123.89, 126.00, 133.96, 134.49, 136.06, 136.49, 138.98, 147.35, 151.39, 162.98, 170.62. HRMS (ESI): *m/z* [M+Na]<sup>+</sup> calcd for C<sub>20</sub>H<sub>18</sub>N<sub>4</sub>O<sub>7</sub>Na: 449.1073, found: 449.1076.

#### 4.1.4. 1-Acetyl-3a,5-dihydroxy-N-(2-isopropylphenyl)-2,3,3a,8a-tetrahydropyrrolo[2,3-b]indole-8(1H)-carboxamide 10

The residue was purified by column chromatography (silica gel, 0–5% MeOH–Et<sub>2</sub>O) to give a white solid; yield: 92 mg (31%); mp 265–266 °C. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ = 1.22 (d, 6 H, *J* = 7.8 Hz, (CH<sub>3</sub>)<sub>2</sub>CH), 2.17 (s, 3 H, COCH<sub>3</sub>), 2.45 (m, 2 H, CH<sub>2</sub>), 3.14 (m, 2 H, (CH<sub>3</sub>)<sub>2</sub>CH, CHH), 3.92 (m, 1 H, CHH), 5.89 (s, 1 H, *H*-8a), 6.78 (dd, 1 H, *J*<sub>1</sub> = 2.0 Hz, *J*<sub>2</sub> = 8.5 Hz), 7.18 (m, 2 H), 6.87 (d, 1 H,

*J* = 2.5 Hz), 7.30 (dd, 1 H, *J*<sub>1</sub> = 2.0 Hz, *J*<sub>2</sub> = 7.5 Hz), 7.34 (dd, 1 H, *J*<sub>1</sub> = 2.0 Hz, *J*<sub>2</sub> = 7.5 Hz), 7.45 (d, 1 H, *J* = 9.0 Hz). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): δ = 22.08, 24.13, 30.74, 38.21, 48.66, 84.14, 87.55, 110.84, 117.89, 120.36, 126.78, 126.99, 127.35, 128.20, 134.51, 136.29, 137.83, 145.40, 155.53, 157.75, 174.15. HRMS (ESI): *m/z* [M+Na]<sup>+</sup> calcd for C<sub>22</sub>H<sub>25</sub>N<sub>3</sub>O<sub>4</sub>Na: 418.1743, found: 418.1746. X-ray analysis<sup>2</sup>.

#### 4.1.5. 1-Acetyl-3a,5-dihydroxy-N-(4-isopropylphenyl)-2,3,3a,8a-tetrahydropyrrolo[2,3-b]indole-8(1H)-carboxamide 12

The residue was purified by column chromatography (silica gel, 0–5% MeOH–Et<sub>2</sub>O) to give a white solid; yield: 65 mg (24%); mp 166–169 °C. <sup>1</sup>H NMR (200 MHz, CD<sub>3</sub>OD): δ = 1.22 (d, 6 H, *J* = 7.8 Hz, (CH<sub>3</sub>)<sub>2</sub>CH), 2.17 (s, 3 H, COCH<sub>3</sub>), 2.40 (m, 2 H, CH<sub>2</sub>), 2.85 (quin, 1 H, *J* = 6.4 Hz, (CH<sub>3</sub>)<sub>2</sub>CH), 3.08 (m, 1 H, CHH), 3.87 (m, 1 H, CHH), 5.81 (s, 1 H, *H*-8a), 6.78 (dd, 1 H, *J*<sub>1</sub> = 2.4 Hz, *J*<sub>2</sub> = 8.6 Hz), 6.86 (d, 1 H, *J* = 2.6 Hz), 7.15 (d, 2 H, *J* = 8.4 Hz), 7.40 (d, 2 H, *J* = 8.6 Hz), 7.47 (d, 1 H, *J* = 8.6 Hz). <sup>13</sup>C NMR (50 MHz, CD<sub>3</sub>OD): δ = 22.30, 24.69, 34.96, 38.27, 48.72, 84.03, 87.63, 110.99, 118.02, 120.50, 121.12, 127.75, 134.81, 137.73, 138.47, 144.96, 155.69, 156.40, 174.52. HRMS (ESI): *m/z* [M+Na]<sup>+</sup> calcd for C<sub>22</sub>H<sub>25</sub>N<sub>3</sub>O<sub>4</sub>Na: 418.1743, found: 418.1745. X-ray analysis<sup>3</sup>.

#### 4.1.6. 1-Acetyl-3a,5-dihydroxy-N-(2-methoxyphenyl)-2,3,3a,8a-tetrahydropyrrolo[2,3-b]indole-8(1H)-carboxamide 14

The residue was purified by column chromatography (silica gel, 0–5% MeOH–Et<sub>2</sub>O) to give a white solid; yield: 53 mg (26%); mp 161–164 °C. <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD): δ = 2.14 (s, 3 H, COCH<sub>3</sub>), 2.45 (m, 2 H, CH<sub>2</sub>), 3.08–3.13 (m, 1 H, CHH), 3.33–3.88 (m, 1 H, CHH), 3.88 (s, 3 H, OCH<sub>3</sub>), 5.81 (s, 1 H, *H*-8a), 6.80 (dd, 1 H, *J*<sub>1</sub> = 2.5 Hz, *J*<sub>2</sub> = 8.0 Hz), 6.86 (d, 1 H, *J* = 2.5 Hz), 6.90 (td, 1 H, *J*<sub>1</sub> = 1.5 Hz, *J*<sub>2</sub> = 8.0 Hz), 7.00 (dd, 1 H, *J*<sub>1</sub> = 1.5 Hz, *J*<sub>2</sub> = 8.0 Hz), 7.05 (td, 1 H, *J*<sub>1</sub> = 1.5 Hz, *J*<sub>2</sub> = 8.0 Hz), 7.43 (d, 1 H, *J* = 8.5 Hz), 7.76 (dd, 1 H, *J*<sub>1</sub> = 1.5 Hz, *J*<sub>2</sub> = 7.5 Hz). <sup>13</sup>C NMR (125 MHz, CD<sub>3</sub>OD): δ = 22.15, 37.65, 48.51, 56.49, 84.45, 87.33, 110.91, 112.31, 118.00, 121.09, 121.62, 123.79, 125.46, 129.45, 135.00, 137.80, 152.63, 155.84, 157.08, 174.12. HRMS (ESI): *m/z* [M+Na]<sup>+</sup> calcd for C<sub>20</sub>H<sub>21</sub>N<sub>3</sub>O<sub>5</sub>Na: 406.1379, found: 406.1378.

## Acknowledgment

We thank Krystyna Wojtasiewicz for her valuable technical assistance.

## References

- [1] H. Kato, T. Yoshida, T. Tokue, Y. Nojiri, H. Hirota, T. Ohta, R.M. Williams, S. Tsukamoto, *Angew. Chem. Int. Ed.* 46 (2007) 2254.
- [2] C. Shinohara, K. Harumi, Y. Takei, A. Endo, *J. Antibiot.* 47 (1994) 163.
- [3] K.S. Lam, G.A. Hesler, J.M. Mattel, S.W. Mamber, S. Forenza, K. Tomita, *J. Antibiot.* 43 (1990) 956.
- [4] (a) T. Iwaki, F. Yamada, S. Funaki, M. Somei, *Heterocycles* 65 (2005) 1811;  
(b) A.J. Oelke, F. Antonietti, L. Bertone, P.B. Cranwell, D.J. France, R.J.M. Goss, T. Hofmann, S. Knauer, S.J. Moss, P.C. Skelton, R.M. Turner, G.

- Wuitschik, S.V. Ley, *Chem. Eur. J.* 17 (2011) 4183 ;  
(c) A. Singh, G.P. Roth, *Tetrahedron Lett.* 53 (2012) 4889.
- [5] (a) M. Nakagawa, Y. Yokoyama, S. Kato, T. Hino, *Tetrahedron* 41 (1985) 2125 ;  
(b) A. Sakai, H. tani, T. Aoyama, T. Shioiri, *Synlett* 3 (1998) 257.
- [6] M. Nakagawa, J. Chiba, T. Hino, *Heterocycles* 9 (1978) 385.
- [7] (a) A. Siwicka, Z. Molęda, K. Wojtasiewicz, A. Zawadzka, J.K. Maurin, M. Panasiewicz, T. Pacuska, Z. Czarnocki, *J. Pineal Res.* 45 (2008) 40 ;  
(b) Z. Molęda, K. Wojtasiewicz, M. Panasiewicz, Z. Czarnocki, *J. Pineal Res.* 49 (2010) 55.
- [8] P. De Fillipis, M. Scarsella, N. Verdone, *Ind. Eng. Chem. Res.* 48 (2009) 1372.
- [9] J. Dai, Y. Zhang, J. Wang, X. Li, Z. Lu, Y. Cai, X. Qian, *Rap. Commun. Mass. Spectrom* 19 (2005) 1130.
- [10] G.M. Sheldrick, *Acta Crystallorg., Sect. A: Cryst. Phys., Diff., Theor. Gen. Crystallorg.* A64 (2008) 112.